Urinary placental growth factor and risk of preeclampsia

被引:242
作者
Levine, RJ
Thadhani, R
Qian, C
Lam, C
Lim, KH
Yu, KF
Blink, AL
Sachs, BP
Epstein, FH
Sibai, BM
Sukhatme, VP
Karumanchi, SA
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Div, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[4] Allied Technol Grp, Rockville, MD USA
[5] Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA
[6] NICHHD, Div Epidemiol Stat & Prevent Res, US Dept HHS, Bethesda, MD 20892 USA
[7] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[8] Massachusetts Gen Hosp, Dept Obstet, Boston, MA 02114 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 293卷 / 01期
关键词
D O I
10.1001/jama.293.1.77
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Preeclampsia may be caused by an imbalance of angiogenic factors. We previously demonstrated that high serum levels of soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic protein, and low levels of placental growth factor (PIGF), a proangiogenic protein, predict subsequent development of preeclampsia. In the absence of glomerular disease leading to proteinuria, sFlt1 is too large a molecule to be filtered into the urine, while PIGF is readily filtered. Objective To test the hypothesis that urinary PIGF is reduced prior to onset of hypertension and proteinuria and that this reduction predicts preeclampsia. Design, Setting, and Patients Nested case-control study within the Calcium for Preeclampsia Prevention trial of healthy nulliparous women enrolled at 5 US university medical centers during 1992-1995. Each woman with preeclampsia was matched to 1 normotensive control by enrollment site, gestational age at collection of the first serum specimen, and sample Storage time at -70degreesC. One hundred twenty pairs of women were randomly chosen for analysis of serum and urine specimens obtained before labor. Main Outcome Measure Cross-sectional urinary PIGF concentrations, before and after normalization for urinary creatinine. Results Among normotensive controls, urinary PIGF increased during the first 2 trimesters, peaked at 29 to 32 weeks, and decreased thereafter. Among cases, before onset of preeclampsia the pattern of urinary PIGF was similar, but levels were significantly reduced beginning at 25 to 28 weeks. There were particularly large differences between controls and cases of preeclampsia with subsequent early onset of the disease or small-for-gestational-age infants. After onset of clinical disease, mean urinary PIGF in women with preeclampsia was 32 pg/mL, compared with 234 pg/mL in controls with fetuses of similar gestational age (P<.001). The adjusted odds ratio for the risk of preeclampsia to begin before 37 weeks of gestation for specimens obtained at 21 to 32 weeks, which were in the lowest quartile of control PIGF concentrations (<118 pg/mL), compared with all other quartiles, was 22.5 (95% confidence interval, 7.4-67.8). Conclusion Decreased urinary PIGF at mid gestation is strongly associated with subsequent early development of preeclampsia.
引用
收藏
页码:77 / 85
页数:9
相关论文
共 20 条
[1]   VASCULAR-PERMEABILITY FACTOR MESSENGER-RNA AND PROTEIN EXPRESSION IN HUMAN KIDNEY [J].
BROWN, LF ;
BERSE, B ;
TOGNAZZI, K ;
MANSEAU, EJ ;
VANDEWATER, L ;
SENGER, DR ;
DVORAK, HF ;
ROSEN, S .
KIDNEY INTERNATIONAL, 1992, 42 (06) :1457-1461
[2]   INHIBITION OF VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR ACTIVITY BY AN ENDOGENOUSLY ENCODED SOLUBLE RECEPTOR [J].
KENDALL, RL ;
THOMAS, KA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10705-10709
[3]   Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia [J].
Koga, K ;
Osuga, Y ;
Yoshino, O ;
Hirota, Y ;
Xie, RM ;
Hirata, T ;
Takeda, S ;
Yano, T ;
Tsutsumi, O ;
Taketani, Y .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2348-2351
[4]   Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia [J].
Levine, RJ ;
Qian, C ;
LeShane, ES ;
Yu, KF ;
England, LJ ;
Schisterman, EF ;
Wataganara, T ;
Romero, R ;
Bianchi, DW .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 190 (03) :707-713
[5]   Circulating angiogenic factors and the risk of preeclampsia [J].
Levine, RJ ;
Maynard, SE ;
Qian, C ;
Lim, KH ;
England, LJ ;
Yu, KF ;
Schisterman, EF ;
Thadhani, R ;
Sachs, BP ;
Epstein, FH ;
Sibai, BM ;
Sukhatme, VP ;
Karumanchi, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (07) :672-683
[6]   Trial of calcium for preeclampsia prevention (CPEP): Rationale, design, and methods [J].
Levine, RJ ;
Esterlitz, JR ;
Raymond, EG ;
DerSimonian, R ;
Hauth, JC ;
BenCuret, L ;
Sibai, BM ;
Catalano, PM ;
Morris, CD ;
Clemens, JD ;
Ewell, MG ;
Friedman, SA ;
Goldenberg, RL ;
Jacobson, SL ;
Joffe, GM ;
Klebanoff, MA ;
Petrulis, AS ;
RigauPerez, JG .
CONTROLLED CLINICAL TRIALS, 1996, 17 (05) :442-469
[7]   Trial of calcium to prevent preeclampsia [J].
Levine, RJ ;
Hauth, JC ;
Curet, LB ;
Sibai, BM ;
Catalano, PM ;
Morris, CD ;
DerSimonian, R ;
Esterlitz, JR ;
Raymond, EG ;
Bild, DE ;
Clemens, JD ;
Cutler, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (02) :69-76
[8]   Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfimction, hypertension, and proteinuria in preeclampsia [J].
Maynard, SE ;
Min, JY ;
Merchan, J ;
Lim, KH ;
Li, JY ;
Mondal, S ;
Libermann, TA ;
Morgan, LP ;
Sellke, FW ;
Stillman, IE ;
Epstein, FH ;
Sukhatme, VP ;
Karumanchi, SA .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (05) :649-658
[9]   Endothelial dysfunction in preeclampsia [J].
Roberts, JM .
SEMINARS IN REPRODUCTIVE ENDOCRINOLOGY, 1998, 16 (01) :5-15
[10]   High levels of urinary vascular endothelial growth factor in women with severe preeclampsia [J].
Roes, EM ;
Steegers, EAP ;
Thomas, CMG ;
Geurts-Moespot, A ;
Raijmakers, MTM ;
Peters, WHM ;
Sweep, CGJ .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2004, 19 (01) :72-75